SCHEMBL25141389

SCHEMBL25141389

CCOc1ccc2cc(-c3cn(CC(C)(C)O)c4ncnc(NCCO)c34)ccc2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 5/20 0.47
▸ LMNA P02545 2/20 0.47
▸ POLB P06746 2/20 0.42
▸ SRC P12931 5/20 0.42
▸ ABL1 P00519 4/20 0.42
▸ MEN1 O00255 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ HCK P08631 2/20 0.39
▸ EGFR P00533 2/20 0.39
▸ PIK3CD O00329 1/20 0.39
▸ KDR P35968 1/20 0.39
▸ PIK3CA P42336 1/20 0.39
▸ PIK3CB P42338 1/20 0.39
▸ MTOR P42345 1/20 0.39
▸ PIK3CG P48736 1/20 0.39
▸ EPHB4 P54760 1/20 0.39
▸ PRKDC P78527 1/20 0.39
▸ LCK P06239 1/20 0.37
▸ EPHA3 P29320 1/20 0.37
▸ CSK P41240 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL32659780 1.00 MAPT (0.47) MAPTLMNAPOLBSRCABL1
SCHEMBL23630552 0.92 MAPT (0.44) MAPTLMNAPOLBSRCABL1
SCHEMBL32659759 0.92 MAPT (0.44) MAPTLMNAPOLBSRCABL1
SCHEMBL32659773 0.91 MAPT (0.43) MAPTLMNAPOLBSRCABL1
SCHEMBL23630545 0.91 MAPT (0.43) MAPTLMNAPOLBSRCABL1
SCHEMBL23630548 0.90 PRKD3 (0.41) MAPTLMNAMEN1KMT2AADK
SCHEMBL32659781 0.90 PRKD3 (0.41) MAPTLMNAMEN1KMT2AADK
SCHEMBL23630541 0.89 SRC (0.44) MAPTLMNAPOLBSRCABL1
SCHEMBL32659774 0.89 SRC (0.44) MAPTLMNAPOLBSRCABL1
SCHEMBL23630563 0.86 SRC (0.42) MAPTLMNAPOLBSRCABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230125057-A1 Modified Pyrrolo- and Pyrazolo- Pyrimidines for Prostate Cancer Therapy UNIVERSITY OF WASHINGTON 2023-04-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230125057-A1 Modified Pyrrolo- and Pyrazolo- Pyrimidines for Prostate Cancer Therapy PDK2, PDK1, PC MAPT 1534/4885LMNA 4329/4885POLB 474/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback